ISSN: 2161-1149 (Printed)
+44-77-2385-9429
Department of Rheumatology, Rheumatology Associates PLLC, Kentucky, USA
Research Article
Confronting Step Therapy in Rheumatoid Arthritis: A Rheumatology Practice's Experience Using PrismRA to Bypass Ineffective TNF Inhibitor Therapies
Author(s): John Boone*, Gary Crump and Rosie Walters
Objective: Step Therapy (ST) policies are implemented by third-party payers to reduce prescription drug costs in Rheumatoid Arthritis (RA), often resulting in payer preference for a Tumour Necrosis Factor inhibitor (TNFi) after patients fail conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARD) therapy. Commercial availability of PrismRA has provided rheumatologists with a clinically validated, personalized medicine approach for identifying RA patients who might benefit from first-line use of a non-TNFi biologic/targeted synthetic DMARD (b/tsDMARD) after failing csDMARD therapy. We sought to determine the extent to which ST policies impede RA patients’ access to non-TNFi b/tsDMARD therapy when their PrismRA indicated high likelihood of inadequate response to TNFi therapy.
Methods: We performed chart review of all RA pa.. View More»
DOI:
10.35841/2161-1149.23.13.363